Browsing by Author "Ulas, T"
Now showing 1 - 5 of 5
Results Per Page
Sort Options
Item A Real-Life Turkish Experience of Ruxolitinib in Polycythemia VeraSerin, I; Dogu, MH; Ekinci, O; Cagliyan, GA; Bastürk, A; Aras, MR; Demircioglu, S; Turgut, B; Merter, M; Hacioglu, SK; Bagci, M; Albayrak, M; Korkmaz, S; Erkurt, MA; Dal, MS; Dursun, FE; Tombak, A; Aydogdu, I; Ulas, T; Altuntas, FIntroduction: Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV). Methods: A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: >= 35%) by imaging and control of hematocrit levels (<= 45%) compared to baseline. Results: While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman's rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman's rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher's exact test: p=0.033). Conclusion: This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups.Item The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLLAkpinar, S; Dogu, MH; Celik, S; Ekinci, O; Hindilerden, IY; Dal, MS; Davulcu, EA; Tekinalp, A; Hindilerden, F; Ozcan, BG; Hacibekiroglu, T; Erkurt, MA; Bagci, M; Namdaroglu, S; Korkmaz, G; Bilgir, O; Cagliyan, GA; Ozturk, HBA; Serin, I; Tiryaki, TO; Ozatli, D; Korkmaz, S; Ulas, T; Eser, B; Turgut, B; Altuntas, FWe evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months, 146 patients (75%) achieved at least PR; 16 (8.7%) patients discontinued ibrutinib due to adverse events. The results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings. Patients/Methods: A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the par ticipating centers. Results: The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p+ /p53mut). Of the study group, 146 (75%) patients achieved at least PR, while 16 (8.7%) patients discontinued ibrutinib due to TEA. The most common drug-related adverse events were neutropenia (n: 31; 17.4%) and thrombocytopenia (n: 40; 22.3%), which were >= grade 3 in 9 (5%) and 5 (3.9%) patients, respectively. Pneumonia (n: 42; 23.7%) was the most common nonhematologic TEA. Atr ial fibrillation (n: 5; 2.8%) and bleeding (n: 11; 6.3%) were relatively rare dur ing the study period. Within a median follow-up period of 17 (1-74) months, 42 (21%) patients died. The estimated median OS of the study cohort was 52 months. Only the response to ibrutinib (CR/PR vs. SD/PD) was significantly associated with OS. Conclusion: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. (C) 2021 Elsevier Inc. All rights reserved.Item The clinicopathological features and survival of Castleman disease: a multicenter Turkish studyYildiz, J; Bagci, M; Sayin, S; Kaya, A; Yilmaz, F; Ekinci, O; Dal, MS; Basturk, A; Aydogdu, I; Albayrak, M; Dogan, A; Erkurt, MA; Korkmaz, S; Ulas, T; Eser, B; Altuntas, FOBJECTIVE: In this study, we aimed to investigate the clinicopathological features and survival of CD, which is quite rare and has many unknowns. PATIENTS AND METHODS: This study was conducted by retrospectively evaluating patients diagnosed with CD in six different centers in Turkey. RESULTS: The median age of 33 patients included in the study was 49 and 51.5% (n = 17) of these patients were women. 18 (54.5%) patients were in the hyaline vascular subtype and most of the patients were UCD (n = 20, 60.6%). The most common involvement region was head and neck (n = 19, 57.5%). The UCD group was younger than the MCD group (p=0.027). Visceral lymph node involvement was higher in MCD than in UCD (p=0.001). Similarly, it was observed that there was more hepatomegaly (p=0.035) and splenomegaly (p=0.013) in the MCD group. During the median 19.5 months follow-up period, there were no patients who died. CONCLUSIONS: It was observed that UCD and MCD are different clinical entities. Promising survival times can be achieved with surgical and systemic treatments in both subtypes of this extremely rare disease. However, this re- suit should be supported by well-designed prospective comprehensive studies.Item Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in TurkeyBakirtas, M; Dal, MS; Yigenoglu, TN; Giden, AO; Serin, I; Basci, S; Kalpakci, Y; Korkmaz, S; Ekinci, O; Albayrak, M; Basturk, A; Ozatli, D; Dogu, MH; Hacibekiroglu, T; Çakar, MK; Ulas, T; Miskioglu, M; Gulturk, E; Eser, B; Altuntas, FA multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least >= two lines of therapy. Patients' treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 +/- 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients.Item International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry reportOzatli, D; Giden, AO; Erkurt, MA; Korkmaz, S; Basci, S; Ulas, T; Turgut, B; Yigenoglu, TN; Hacibekiroglu, T; Basturk, A; Dal, MS; Namdaroglu, S; Hindilerden, F; Hacioglu, SK; Cagliyan, GA; Ilhan, G; Kacmaz, M; Uysal, A; Merter, M; Ekinci, O; Dursun, FE; Tekinalp, A; Demircioglu, S; Sincan, G; Acik, DY; Akdeniz, A; Ucar, MA; Yeral, M; Ciftciler, R; Teke, HU; Umit, EG; Karakus, A; Bilen, Y; Yokus, O; Albayrak, M; Demir, C; Okan, V; Serefhanoglu, S; Karti, S; Ozkurt, ZN; Eser, B; Aydogdu, I; Kuku, I; Cagirgan, S; Sonmez, M; Ozet, G; Altuntas, FTherapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful sub-stances in the blood that are associated with or cause certain diseases. During the last decades the application of therapeutic apheresis has expanded to a broad spectrum of hematological and non-hematological diseases due to various studies on the clinical efficacy of this procedure. In this context there are more than 30 centers per-forming therapeutic apheresis and registered in the apheresis database in Turkey. Herein, we, The Turkish Apheresis Registry, aimed to analyze some key articles published so far from Turkey regarding the use of apheresis for various indications.